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ABSTRACT 
Mucoadhesive microspheres overcome the physiological adversities like short gastric residence time promoting the drug bioavai lability. In the 
present investigation Nizatidine loaded Eudragit RS 100 microspheres were prepared by solvent evaporation technique using disparate drug 
polymer ratios with Eudragit RS 100 polymer and Nizatidine loaded chitosan microspheres were prepared by coacervation phase s eparation 
method. The prime objective was to enhance the absorption and bioavailability by prolonging the gastric residence time. Totally six 
formulations RES1- RES6 Eudragit RS 100 microspheres and six formulations RCP1 – RCP6 Eudragit RS100 microspheres were prepared and 
evaluated. RES3 and RCP3 showed nearly 90% drug release after 24 h. Hence the Nizatidine loaded Eudragit RS100 microspheres and Chitosan 
microspheres were further studied for the in vivo study for the suitability of the formulation. The bioavailability of nizati dine after oral 
ingestion is about 50% and is absorbed via the small intestine and it may be attributed to permeability of the intestine is relatively slow in 
nature. Hence the current research was to widen the therapeutic efficacy of Nizatidine by formulating microspheres enhance the intestinal 
permeability as well as bioavailability by performing the anti-ulcer activity.  
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INTRODUCTION  
Peptic ulcer is a very common disease escalating throughout 
the world. A peptic ulcer is an erosion or sore in the wall of 
the gastrointestinal tract. The mucous membrane being 
delicate in nature which lines the digestive tract erodes and 
leads to a slow breakdown of tissue. This breakdown yields a 
burning pain in the upper middle part of the belly 
(abdomen). Peptic ulcer disease (PUD) occurs to the 
following:  H pylori infection  Drugs  Lifestyle factors  Severe 
physiologic stress Hypersecretory states (uncommon)  
Genetic factors Nizatidine restrain histamine stimulation of 
the H2 receptor in gastric parietal cells, which consecutively 
reduces gastric acid secretion, gastric volume, and hydrogen 
ion concentrations.1,2 Nizatidine hydrochloride by inhibiting 
basal gastric acid secretion cause depletion of volume of acid 
and pepsin secretion. Nizatidine is administered as often in 
tablet, capsule, syrup and injection but the bioavailability is 
less. Hence to elevate the peptic ulcer pain the present work 
comprises of formulating Nizatidine as mucoadhesive 
microspheres since mucoadhesive microspheres form an 
integral part of novel drug delivery systems. Mucoadhesive 
microspheres provides numerous advantages such as 
effective drug absorption and intensified bioavailability of 
drugs due to a high surface-tovolume ratio and enormous 
intimate contact with the mucus layer, and specific targeting 
of drugs to the absorption site. Mucoadhesive microspheres 
being adhered to the stomach wall and thereby remain in the 
gastrointestinal tract for a longer time period. In recent 
years, mucoadhesive microspheres attention has been 
greatly focused since drug releases to the need of the body 
throughout the period of treatment and it provides the 
active entity solely to the site of action.3, 5 
MATERIALS AND METHODS 
Chemicals  
Nizatidine was obtained from SMS Pharmaceuticals Pvt. Ltd. 
(Hyderabad, India) as free gift sample. PEG-400 was 
purchased from BD Pharmaceuticals Ltd. (Kolkata, India), 
and Tween80 was purchased from Merck Specialties Pvt. 
Ltd. (Mumbai, India). All other chemicals used in this study 
were obtained commercially and were of analytical (AR) 
grade. 
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Preparation of microspheres by solvent evaporation 
technique  
Nizatidine loaded Eudragit Rs 100 microspheres were 
prepared by solvent evaporation. The Nizatidine 
microspheres were prepared with various ratios of drug and 
Eudragit RS100 polymer as shown in Table 1 using solvent 
evaporation technique. The method is a modification of 
emulsion solvent evaporation technique and involves 
preparation of o/w emulsion between organic phase 
consisting of Nizatidine and Eudragit RS 100 in 
dichloromethane (DCM) and aqueous phase, 1% w/v 
aqueous solution of polyvinyl alcohol (PVA).The 
dichloromethane solution of Nizatidine and Eudragit RS100 
was emulsified by using probe homogenizer (Virtis Cyclone 
IQ, USA).The dichloromethane was completely evaporated 
by stirring overnight(12 to 16 hrs) at room temperature 
(250C±20C). The prepared microspheres were recovered by 
centrifugation for 20 minutes at 15,000rpm [Sorvall 
Ultracentrifuge, USA]. The precipitate was washed 
repeatedly with ice cold water to remove the traces of 
polyvinyl alcohol. Finally, the product was dispersed in cold 
water and recovered by lyophilisation (Labconco 
Lyophilisor, USA). Six batches of Eudragit microspheres 
were prepared keeping organic phase to aqueous phase at 
1:5, and varying drug: polymer ratios. The 
biopharmaceutical parameters of dosage forms can be 
achieved directly by measuring the drug blood levels as a 
function of time or indirectly by measuring 
pharmacodynamic response as a function of time.6  
Preparation of Nizatidine microspheres by 
coacervation- phase separation method  
The Nizatidine loaded chitosan microspheres were prepared 
by coacervationphase separation technique using various 
ratios of drug and polymer. The polymeric solution was 
prepared by dissolving the chitosan in DCM. Then Nizatidine 
was dissolved in the polymeric solution and sonicated for 5 
min. The organic non-solvent liquid paraffin was added to 
the polymeric solution at the rate of 1ml/min under 
continuous stirring using mechanical stirrer with 600 rpm. 
The slow addition of liquid paraffin coacervates the polymer 
in the mixture. The coacervate phase is then added to the 
hexane (non-solvent) under gentle stirring to harden the 
coating layer. The formed microspheres were then 
centrifuged for 10 min at 10,000 rpm. The precipitate was 
then collected and washed at least three times with distilled 
water. The prepared microspheres were lyophilized and 
stored in container for further studies. Six batches of 
microspheres were prepared using various ratios of drug: 
polymer Selected formulations of Nizatidine microparticles 
prepared by Eudragit RS100 and Chitosan were subjected to 
in vivo studies in animal model. The in vivo anti ulcer 
activity and bioavailability study were carried out in rat 
model. Rats are widely used for in vivo bioavailability study 
as well as anti ulcer activity study, as its physiological 
structure is similar to human model. Moreover rats are easy 
to handle and are low in cost.7  
Animals  
Albino rat of either sex weighing 400 – 450 gm were chosen 
for this experiment. Institutional animal ethics committee 
approved the experimental protocol; animal were 
maintained under standard condition in an animal house 
approved by committee for the purpose of control and 
supervision on experiment on animal. All animal 
experiments were approved by Institutional animal ethics 
committee (IAEC) of Registration No. 
1546/PO/E/S/11/CPCSEA. 
Animals were kept in standard cages for constant room 
temperature at 25 ± 1 0C. Rats were kept  in Fasted condition for 
18 hour where no food but water was provided ad-libitum and 
had free access to water. 
 In vivo anti-ulcer activity  
The anti-ulcer activity of the formulation was carried out in Albino 
rat. The oral dose of 20 mg/kg was chosen for this purpose. The 
healthy rats were divided into four groups with five animal each. 
The animals in the test groups were administered 1ml / 100 gm of 
rat with necrotizing agent (80% ethanol) orally which is known to 
produce gastric lesions. The dosage schedule for the study is as 
follows  
Group 1: Animals were given the normal saline with dose of  
10 ml / Kg and served as negative control. Group 2: Animals 
were administered with Ethanol (80% )  orally and served as 
positive control. Group 3: Animals were administered 
ethanol 1 ml /100gm and treated with pure Nizatidine 
20mg/kg. Group 4: Animals were administered with ethanol 
and treated with formulation (equivalent 20 mg 
Nizatidine).Group 5: the animals administered with ethanol 
and treated with RCP3 (equivalent of 20 mg Nizatidine) 
According to the gastric emptying in fasted rats, 
formulations was given 30 minute before the ethanol 
administration.  Animals were sacrificed under anesthesia 1 
hr after treatment with formulation. The stomach was 
excised and opened along the greater curvature and after 
washing with normal saline, the gastric lesions were 
quantified using a magnifying glass. and ulcer index (UI) was 
estimated.  
                              UI   =           Ulcerated area (mm2)  
                                              Total stomach area (mm2) 
In vivo Bioavailability study  
The bioavailability study was carried out in albino rats of 
either sex weighing 200 – 250 gm. The animal were divided 
into three groups of five animals each and were fasted 
overnight before starting the experiment with free access to 
water. The pure Nizatidine and prepared microspheres 
formulation was administered orally with dose 20mg/kg 
body weight with the help of cannula after anaesthetizing for  
a very short period of time with diethyl ether , after 
administration 0.3 ml blood samples were collected from 
retro- orbital plexus into the heparinized tubes at pre set 
period of 0.5, 1,2,4,8,12,24h. The blood samples were 
centrifused at 4000rpm for 10 minutes and the separated 
samples were stored at  - 20 0C  until analysis had 
completed.  
Estimation of Nizatidine in plasma sample by RP-HPLC 
analysis 
The amount of Nizatidine in blood samples was measured by RP-
HPLC method (Haque et al., 2011.The method was validated prior 
estimation. The measurement was carried out at 280 nm .The 
mobile phase used consist of mixture of 0.1(M) orthophosphoric 
acid (PH 3.0) and methanol in the ratio of 30:70  and the pump flow 
rate was 1ml/min and C18 (250mm × 4.6 mm) column was 
used..The mobile phase was filtered with nylon membrane filter 
and degassed before use.  
To 0.1 ml plasma 50 μL of standard nizatidine (50 ng/ml) was 
added in a micro centrifuge tube and volume was made up to 2 ml 
with acetonitrile to precipitate the protein. Then tha sample was 
centrifuged at 4000 rpm for 25 min. The supernatant was 
collected and transferred into an eppendorf  tube and was dried. 
The residue was dissolved in 200  μL of mobile phase and 10 μL 
was injected to the HPLC system. The analysis was carried out by 
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RP-HPLC method using flow rate 1.0 ml/min and measurement 
was made at 280 nm. The amount of the nizatidine in the sample 
was determined from the  peak area ratio correlated with 
standard curve prepared under the same identical condition. 
Pharmacokinetic Analysis  
Determination of Cmax and Tmax 
The peak plasma concentration (Cmax) and the time of peak plasma 
concentration (Tmax) were determined from the plasma drug 
concentration vs time plot for the pure drug and prepared 
microspheres. 
Determination of area under curve (AUC):  
The area under the time versus plasma concentration curve  
(AUC) was measured by applying trapezoidal rule . (AUC) 0-α  
was calculated as given below  
(AUC) 0 –t   = ∫  
 
 
C(t) dt 
(AUC) 0 –α   = (AUC) 0-t + C t / Kel 
Determination of  relative  Bioavailability  
The relative bioavailability (Fr) of Nizatidine was calculated 
using the following equation: 
Fr (%) =   
                            
                           
RESULTS AND DISCUSSION 
Optimized formulation In the present study mucoadhesive 
microspheres using chitosan and Eudragit RS 100 of Nizatidine 
hydrochloride were successfully prepared by solvent evaporation 
technique. The formulations RES3 and RCP3were selected as an 
ideal formulation based in vitro drug release tests. Formulation 
and evaluation of Nizatidine loaded chitosan and Eudragit RS 100 
microspheres for controlled release was found to be potential and 
effective in terms yield, encapsulation efficiency, particle size 
distribution. RES3 formulation drug release was slow and 
extended beyond 12 hr up to 24 hr which could be the constant 
release of drug which has been loaded near the surface of 
microspheres. Kinetic results reveals microspheres obeyed 
Higuchi and Peppas model.RCP3formulations showed slow drug 
release which extended beyond 12 hr up to 24 hr. The formulation 
showed rapid drug release after 4 hr and this could be result of 
polymer erosion in the surface of microspheres and obeyed 
Higuchi and as well as Peppas model indicating the diffusion drug 
release mechanism. Hence the optimized RES3 and RCP3 
formulations of Nizatidine mucoadhesive microspheres were 
selected for invivo anti ulcer activity study and invivo 
bioavailability study. 
In-vivo anti-ulcer activity study  
Ethanol is considered a major risk factor for the gastric ulcer. The 
ethanol penetrates the gastric mucosa in the stomach due to its 
ability to solubilize the mucous on the membrane. Once the 
mucous get solubilized the membrane becomes exposed to the 
proteolytic enzyme pepsin and hydrochloric acid in the stomach 
causing the damage to the membrane. The rat model is widely 
used for antiulcer activity as its physiological structure is 
resembled to the human. In the present study the anti-ulcer 
activity of the prepared microspheres formulations (RES3 and 
RCP3) was evaluated in the ethanol induced ulcerative rats by 
measuring the ulcer index. The ulcer index is given in table 1. The 
ulcer index value in the ethanol treated group was 23.92 ± 0.58, 
whereas, the normal saline treated group showed no ulcer owing 
to the lower value. The ulcer index of the formulations RES3 and 
RCP3 was notably reduced as compared to ethanol treated group, 
but this value is remarkably reduced for the pure drug treated 
group as compared to the positive control group. The percentage 
of ulcer protection of the pure Nizatidine and the formulations 
RES3 and RCP3 was given in figure 1. 
 
 
Figure - 1:  Anti-ulcer activity of the Nizatidine formulations RES3 and RCP3 
 
The ulcer protection of the microspheres formulations RES3 and 
RCP3 were 79.84% and 76.49% respectively as compared to the 
Nizatidine pure drug (66.05%) in ulcer induced rats. The pure 
Nizatidine showed poor activity against mucosal damage as 
compared to the microspheres. The improve activity of the 
microspheres was because of sustained release property as well as 
mucoadhesive property of the RES3 and RCP3, which suggests 
that Nizatidine microspheres strengthens and protects the gastric 
mucosal barrier 3.3. In vivo bioavailability study The availability of 
the drug to the biological system and its therapeutic effectiveness 
is the goal of any dosage form design. The bioavailability study of 
the two microsphere formulations RES3 and RCP3 were carried 
out in the rat model. The rat model is widely used for 
bioavailability study for many drugs. The plasma drug 
concentration-time profile of Nizatidine was constructed following 
the oral administration of pure Nizatidine and Nizatidine loaded 
microspheres at a dose of 20 mg/kg to rats (table 2). The plasma 
concentration-time profile is illustrated in figure 2 and the 
pharmacokinetic parameters are listed in table 3. The plasma 
concentration time profile of Nizatidine pure drug showed the 
higher peak than that of formulation RES3 and RCP3. The C max 
value of Nizatidine as obtained from the graph was 575.14 ± 55.43 
ng/ml with T max value 2 h and for formulations RES3 and RCP3 C 
max were 206.58 ± 7.71 and 221.52 ± 9.42 ng/ml respectively. 
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 Table 1: Anti-ulcer activity of the Nizatidine formulations RES3 and RCP3 in ethanol induced ulcer in rat 
Groups                      Induction Dose   Ulcer Index 
               Group – I                                                                Normal Saline             10ml/kg                                           1.090 ±0.04 
              Group –II                                                                Ethanol                                                       1ml/gm                                              23.92 ± 0.58 
                Group –III                                                               Nizatidine                                                  20 mg/kg                                          8.12 ± 0.28** 
                  Group – IV                                                              RES3                                                             20 mg/kg                                          4.83± 0.86*   
                 Group – V                                                               RCP3                                                             20 mg/kg                                          5.63 ±0 .46* 
     Note : Values express mean ± SEM ; n=4; *p<.0.05 bversus control, **p<0.01versus control 
 
Table 2: Drug Plasma concentration vs. Time data following oral administration of pure Nizatidine (Standard) to rat. 
 
Plasma Concentration in ng / ml  vs. Time 
 
Time (Hrs.)          Pure Nizatidine                                   RES3                         RCP3 
                       0                                0                                                     0                                0 
                     1.5                      269.65± 42.31                                       45.250±8.42                 40.250 ± 5.560 
                      1                        391.72±56.25                                        69.250± 9.81                79.760 ± 10.03 
                      2                       575.14±55.43                                       138.26±13.94               169.50 ± 13.26 
                      4                      283.5±33.960                                        189.250 ±7.03              197.75 ± 14.23 
                      8                       61.790±7.720                                        206.58± 7.71*              221.52 ± 9.42* 
                     12                     16.430±4.570                                         97.750±10.38               112.75 ± 12.37 
                     24                        _                                                       22.500± 9.600             29.500 ± 7.920 
               Note : Values express mean ± SEM ; n=4; *p<.0.05 versus control, 
 
Table 3: Phamacokinetic Profile of pure Nizatidine and Nizatidine loaded Microspheres after oral 
administration in rats. 
Pharmacokinetics        Units                       Nizatidine Standard             RES3                RCP3 
Parameters     
                Cmax                                              ng / ml                    575.14±55.43                            206.58±7.71         221.52 ± 9.42 
             Tmax                                             H                               2 ± 0                                                  8 ± 0                         8 ± 0 
             AUC (0-24)                               h x (ng / ml)         2064.07                                  2272.22              2408.46 
             Fr                                 (%)                             _                                              110.07                116.68 
 
 
The drug release from the ranitidine microspheres extend up 
to 24h as the formulations showed sustained release 
properties as evidenced from the in vitro drug release study. 
The AUC (0-24) of the formulations were higher than the 
AUC (0-24) of the pure ranitidine, which proves the better 
bioavailability of the microspheres and better therapeutic 
effect for the management of gastric and peptic ulcer. 
CONCLUSIONS 
In the present investigation, the utility of microsphere as 
carrier for oral delivery of Nizatidine was studied. The 
Nizatidine loaded microspheres were prepared by emulsion 
solvent evaporation method and coacervation phase 
separation method. The pharmacodynamic study (ethanol-
induced ulcer model) revealed that Nizatidine microspheres 
showed lower incidence of mucosal damage when compared 
with standard drug, both administered orally, indicating the 
superiority of oral Nizatidine microspheres over standard 
ranitidine. The pharmacokinetic studies reveal that the oral 
administration of Nizatidine microspheres sustained the 
release of drugs over 24 hrs. The drug release from the 
microspheres showed controlled drug release mechanism. 
Enhanced antiulcer efficacy was obtained with reduction in 
gastric acid secretion. As a consequence of this, decrease in 
the dose and frequency of administration for drugs is 
possible to achieve the desired therapeutic activity. 
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